Figure 3From: Mechanism-related circulating proteins as biomarkers for clinical outcome in patients with unresectable hepatocellular carcinoma receiving sunitinibReceiver operating characteristic (ROC) curves for prediction of disease control (partial response [PR] or stable disease [SD] > 12 weeks) by baseline level of soluble protein. Arrows indicate ROC curve-derived cut-points.Back to article page